...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection and immunity >Protective Efficacy and Safety of Brucella melitensis 16MΔmucR against Intraperitoneal and Aerosol Challenge in BALB/c Mice
【24h】

Protective Efficacy and Safety of Brucella melitensis 16MΔmucR against Intraperitoneal and Aerosol Challenge in BALB/c Mice

机译：布鲁氏菌16MΔmucR对BALB / c小鼠腹腔和气溶胶攻击的保护作用和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Brucellosis is a zoonosis of nearly worldwide distribution. Vaccination against this pathogen is an important control strategy to prevent the disease. Currently licensed vaccine strains used in animals are unacceptable for human use due to undesirable side effects and modest protection. Substantial progress has been made during the past 10 years toward the development of improved vaccines for brucellosis. In part, this has been achieved by the identification and characterization of live attenuated mutants that are safer in the host but still can stimulate an adequate immune response. In the present study, the identification and characterization of the mucR mutant (BMEI 1364) as a vaccine candidate for brucellosis was conducted. BALB/c mice were vaccinated intraperitoneally at a dose of 105 CFU with the mutant to evaluate safety and protective efficacy against intraperitoneal and aerosol challenge. All animals vaccinated with the vaccine candidate demonstrated a statistically significant degree of protection against both intraperitoneal and aerosol challenge. Safety was revealed by the absence of Brucella associated pathological changes, including splenomegaly, hepatomegaly, or granulomatous disease. These results suggest that the 16MΔmucR vaccine is safe, elicits a strong protective immunity, and should be considered as a promising vaccine candidate for human use.
机译：布鲁氏菌病是一种几乎遍布全球的人畜共患病。针对这种病原体的疫苗接种是预防该病的重要控制策略。由于不良的副作用和适度的保护，目前在动物中使用的已获许可的疫苗株不能用于人类。在过去的十年中，在开发用于布鲁氏菌病的改良疫苗方面已经取得了实质性进展。在某种程度上，这是通过鉴定和鉴定活的减毒突变体实现的，这些突变体在宿主中更安全，但仍然可以刺激足够的免疫反应。在本研究中，进行了 mucR 突变体（BMEI 1364）作为布鲁氏菌病候选疫苗的鉴定和表征。以10 5 CFU的剂量将BALB / c小鼠腹膜内接种该突变体，以评估其对腹膜内和气溶胶激发的安全性和防护效果。接种了候选疫苗的所有动物均表现出统计学上显着的针对腹膜内和气溶胶激发的保护作用。缺乏布鲁氏菌相关的病理变化（包括脾肿大，肝肿大或肉芽肿性疾病）表明安全性。这些结果表明，16MΔ mucR 疫苗是安全的，具有很强的保护性免疫力，应被视为有前途的人用疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号